Focused On-demand Library for Collectin-10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9Y6Z7

UPID:

COL10_HUMAN

Alternative names:

Collectin liver protein 1; Collectin-34

Alternative UPACC:

Q9Y6Z7; Q3SYH6; Q6UW19

Background:

Collectin-10, also known as Collectin liver protein 1 or Collectin-34, is a lectin that exhibits a strong affinity for various sugars, with a preference hierarchy of galactose > mannose = fucose > N-acetylglucosamine > N-acetylgalactosamine. This protein plays a crucial role in the immune system by acting as a chemoattractant, which is likely involved in regulating cell migration.

Therapeutic significance:

Collectin-10 is implicated in 3MC syndrome 3, a genetic disorder characterized by a spectrum of anomalies including facial dysmorphism, craniosynostosis, and learning disabilities. Understanding the role of Collectin-10 could open doors to potential therapeutic strategies for treating or managing this complex syndrome.